Prostate Cancer Detection Clinical Trial
Official title:
Zinc/PSA Ratio as a Novel Biomarker for Prostate Cancer Detection
NCT number | NCT02013180 |
Other study ID # | Zinc/PSA |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | July 2012 |
Est. completion date | January 2017 |
Verified date | November 2017 |
Source | Bagcilar Training and Research Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Although Prostate Specific Antigen (PSA) is a useful marker for early detection of the
prostate cancer, its specivity is not sufficient. Several PSA variations were defined in
order to increase the specivity of the test, but they aren't much more effective than the PSA
alone for detection of disease.
In older studies reported that, serum and prostatic tissue zinc levels decreased in prostat
cancer disease.
In our study we aimed to establish the utility of serum zinc, PSA, free PSA/PSA (fPSA/tPSA),
zinc/PSA, levels for early detection of the prostate cancer.
Status | Completed |
Enrollment | 480 |
Est. completion date | January 2017 |
Est. primary completion date | January 2013 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | N/A and older |
Eligibility |
Inclusion Criteria: Patients with LUTS and elevated serum PSA levels and/or suspicious rectal examination Exclusion Criteria: usage of zinc included drugs, older prostatic operations, older prostatic radiotherapy, older prostatic biopsies, chronic rectal diseases (anal fissure, hemorrhoid, etc..), PIN(prostatic intraepithelial neoplasia) and ASAP(atypical small acinar proliferation) in pathologic evaluation. |
Country | Name | City | State |
---|---|---|---|
Turkey | Bagcilar Training and Research Hospital-Depertmant of Urology | Istanbul | Bagcilar |
Lead Sponsor | Collaborator |
---|---|
Bagcilar Training and Research Hospital |
Turkey,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Assesment of Serum Zinc/PSA Ratio in Patients With Prostate Cancer and Benign Prostatic Diseases | Does the zinc/PSA ratio show statistically signifacant difference in patients with prostate cancer? | measurement of serum zinc and PSA levels are performed prior to transrectal prostat biopsy; pathologic evaluation of biopsy specimens are performed within 2-3 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04291742 -
Comparison of Prostate Fusion Biopsies With Software and Cognitive
|
N/A |